Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Enrolling

Phase 4

Conditions

Radiotherapy Side Effect

Radiotherapy; Complications

Cervical Cancer

Treatments

Drug: KANG FU PEN

Study type

Interventional

Funder types

Other

Identifiers

NCT04819685

KFP for RTI rectal injury

Details and patient eligibility

About

A total of 520 cases will be randomly divided into Kang Fu Pen (liquid dressing) enema intervention group (experimental group) and non-enema intervention group (control group), according to the ratio of 1:1.

Full description

All patients are planned to receive radical concurrent chemoradiotherapy. Intensity modulated radiotherapy (IMRT) will be used for external irradiation, with a dose of 45-50.4Gy /25-28 fractions. Combined three-dimensional intracavitary/interstitial (IC/IS) brachytherapy was applied. The preferred dose fraction plan is 6Gy*5 fractions, or 7Gy*4 fractions. Whether to adopt supplement radiotherapy can be decided by the tumor regression. Cisplatin 40 mg/m2 is recommended as the first choice for concurrent chemotherapy, and TP or TC can also be considered. Single-drug weekly therapy should be completed for at least 3 cycles, and combined 3-week regimen should be completed for at least 1 cycle.

Experimental group: from three days before radiotherapy to one week after radiotherapy, Kang Fu Pen (recombinant human superoxide dismutase) retention enema, 50ml/ time, once every other day. When rectal mucosa II degree reactions (NCI-CTCAE 5.0) occur, it is changed to 1 day/time until 1 week after mucosal remission.

Control group: 3 days before radiotherapy to the end of radiotherapy, no drug retention enema was used.

Enrollment

520 estimated patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient is completely voluntary and has the ability to sign the research informed consent form within 30 days before enrollment;
Age ≥18 years old and ≤65 years old;
Pathologically confirmed cervical cancer;
Those with IB3, IIA2, IIB, IIIA, IIIB, and those with cervical tumor ≥ 4cm or involved parametrial in IIIC1 and IIIC2 (FIGO 2018 staging);
ECOG score 0-2 points;
The complete blood count and basal metabolic indexes in the 14 days before enrollment must meet the following requirements: NEUT≥1.5*10^9/L, HGB≥80g/L, PLT≥100*10^9/L, blood creatinine < 1.5mg/dl (133umol/L), AST and ALT are within 2 times of the upper limit of normal;
Those who have had regular bowel movements and had a negative stool routine test + occult blood before enrollment.

Exclusion criteria

Those who have a history of allergy to superoxide dismutase use;
Patients with skin and mucous membrane infections, patients with obvious empyema or pelvic inflammatory disease;
Those who have had chronic colitis, ulcerative colitis, and non-specific proctitis in the past;
Those who have received cervical cancer surgery (including pelvic or retroperitoneal lymphadenectomy, excluding tumor biopsy), radiotherapy or chemotherapy;
Those who are expected to be unable to receive brachytherapy, or brachytherapy needs to use tumor elimination, uterine tube inserted alone in one fraction, or template plan;
Those who need to use fluorouracil or capecitabine or tigio in the concurrent chemotherapy regimen;
History of other malignant tumors;
Pregnant or lactating women;
Accompanied by active infection and fever;
Other serious diseases that may significantly affect the compliance of clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment.